vs

Side-by-side financial comparison of Quest Diagnostics (DGX) and Invesco (IVZ). Click either name above to swap in a different company.

Quest Diagnostics is the larger business by last-quarter revenue ($2.9B vs $1.7B, roughly 1.7× Invesco). Quest Diagnostics runs the higher net margin — 9.7% vs -58.9%, a 68.6% gap on every dollar of revenue. On growth, Quest Diagnostics posted the faster year-over-year revenue change (9.2% vs 6.2%). Over the past eight quarters, Quest Diagnostics's revenue compounded faster (9.9% CAGR vs 7.1%).

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

DGX vs IVZ — Head-to-Head

Bigger by revenue
DGX
DGX
1.7× larger
DGX
$2.9B
$1.7B
IVZ
Growing faster (revenue YoY)
DGX
DGX
+2.9% gap
DGX
9.2%
6.2%
IVZ
Higher net margin
DGX
DGX
68.6% more per $
DGX
9.7%
-58.9%
IVZ
Faster 2-yr revenue CAGR
DGX
DGX
Annualised
DGX
9.9%
7.1%
IVZ

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
DGX
DGX
IVZ
IVZ
Revenue
$2.9B
$1.7B
Net Profit
$281.0M
$-995.9M
Gross Margin
Operating Margin
15.4%
-86.2%
Net Margin
9.7%
-58.9%
Revenue YoY
9.2%
6.2%
Net Profit YoY
12.0%
-575.8%
EPS (diluted)
$2.24
$-2.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DGX
DGX
IVZ
IVZ
Q1 26
$2.9B
Q4 25
$2.8B
$1.7B
Q3 25
$2.8B
$1.6B
Q2 25
$2.8B
$1.5B
Q1 25
$2.7B
$1.5B
Q4 24
$2.6B
$1.6B
Q3 24
$2.5B
$1.5B
Q2 24
$2.4B
$1.5B
Net Profit
DGX
DGX
IVZ
IVZ
Q1 26
$281.0M
Q4 25
$245.0M
$-995.9M
Q3 25
$245.0M
$356.4M
Q2 25
$282.0M
$197.4M
Q1 25
$220.0M
$171.1M
Q4 24
$222.0M
$209.3M
Q3 24
$226.0M
$55.0M
Q2 24
$229.0M
$132.2M
Gross Margin
DGX
DGX
IVZ
IVZ
Q1 26
Q4 25
32.4%
Q3 25
33.7%
Q2 25
34.2%
Q1 25
32.5%
Q4 24
32.7%
Q3 24
32.6%
Q2 24
33.5%
Operating Margin
DGX
DGX
IVZ
IVZ
Q1 26
15.4%
Q4 25
13.8%
-86.2%
Q3 25
13.7%
16.5%
Q2 25
15.9%
14.1%
Q1 25
13.0%
18.1%
Q4 24
13.8%
19.6%
Q3 24
13.3%
6.6%
Q2 24
14.8%
13.9%
Net Margin
DGX
DGX
IVZ
IVZ
Q1 26
9.7%
Q4 25
8.7%
-58.9%
Q3 25
8.7%
21.7%
Q2 25
10.2%
13.0%
Q1 25
8.3%
11.2%
Q4 24
8.5%
13.1%
Q3 24
9.1%
3.6%
Q2 24
9.6%
8.9%
EPS (diluted)
DGX
DGX
IVZ
IVZ
Q1 26
$2.24
Q4 25
$2.18
$-2.61
Q3 25
$2.16
$0.66
Q2 25
$2.47
$-0.03
Q1 25
$1.94
$0.38
Q4 24
$1.95
$0.46
Q3 24
$1.99
$0.12
Q2 24
$2.03
$0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DGX
DGX
IVZ
IVZ
Cash + ST InvestmentsLiquidity on hand
$393.0M
$1.0B
Total DebtLower is stronger
$5.7B
$1.8B
Stockholders' EquityBook value
$7.7B
$12.2B
Total Assets
$16.7B
$27.1B
Debt / EquityLower = less leverage
0.74×
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DGX
DGX
IVZ
IVZ
Q1 26
$393.0M
Q4 25
$420.0M
$1.0B
Q3 25
$432.0M
$973.1M
Q2 25
$319.0M
$922.7M
Q1 25
$188.0M
$821.7M
Q4 24
$549.0M
$986.5M
Q3 24
$764.0M
$1.0B
Q2 24
$271.0M
$878.5M
Total Debt
DGX
DGX
IVZ
IVZ
Q1 26
$5.7B
Q4 25
$5.2B
$1.8B
Q3 25
$5.2B
$1.6B
Q2 25
$5.2B
$1.9B
Q1 25
$5.9B
$964.8M
Q4 24
$5.6B
$890.6M
Q3 24
$5.6B
$890.3M
Q2 24
$3.8B
$890.1M
Stockholders' Equity
DGX
DGX
IVZ
IVZ
Q1 26
$7.7B
Q4 25
$7.2B
$12.2B
Q3 25
$7.3B
$14.0B
Q2 25
$7.2B
$13.9B
Q1 25
$6.9B
$14.7B
Q4 24
$6.8B
$14.6B
Q3 24
$6.8B
$14.8B
Q2 24
$6.6B
$14.6B
Total Assets
DGX
DGX
IVZ
IVZ
Q1 26
$16.7B
Q4 25
$16.2B
$27.1B
Q3 25
$16.2B
$28.4B
Q2 25
$16.0B
$28.5B
Q1 25
$15.8B
$28.1B
Q4 24
$16.2B
$27.0B
Q3 24
$16.1B
$27.5B
Q2 24
$13.9B
$27.2B
Debt / Equity
DGX
DGX
IVZ
IVZ
Q1 26
0.74×
Q4 25
0.72×
0.15×
Q3 25
0.71×
0.12×
Q2 25
0.72×
0.14×
Q1 25
0.85×
0.07×
Q4 24
0.83×
0.06×
Q3 24
0.83×
0.06×
Q2 24
0.58×
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DGX
DGX
IVZ
IVZ
Operating Cash FlowLast quarter
$278.0M
$455.8M
Free Cash FlowOCF − Capex
$432.2M
FCF MarginFCF / Revenue
25.5%
Capex IntensityCapex / Revenue
3.9%
1.4%
Cash ConversionOCF / Net Profit
0.99×
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DGX
DGX
IVZ
IVZ
Q1 26
$278.0M
Q4 25
$465.0M
$455.8M
Q3 25
$563.0M
$606.2M
Q2 25
$544.0M
$547.9M
Q1 25
$314.0M
$-84.6M
Q4 24
$464.0M
$316.9M
Q3 24
$356.0M
$438.4M
Q2 24
$360.0M
$489.1M
Free Cash Flow
DGX
DGX
IVZ
IVZ
Q1 26
Q4 25
$307.0M
$432.2M
Q3 25
$419.0M
$586.4M
Q2 25
$436.0M
$530.4M
Q1 25
$197.0M
$-108.0M
Q4 24
$341.0M
$309.9M
Q3 24
$250.0M
$410.0M
Q2 24
$268.0M
$462.4M
FCF Margin
DGX
DGX
IVZ
IVZ
Q1 26
Q4 25
10.9%
25.5%
Q3 25
14.9%
35.7%
Q2 25
15.8%
35.0%
Q1 25
7.4%
-7.1%
Q4 24
13.0%
19.5%
Q3 24
10.0%
27.1%
Q2 24
11.2%
31.2%
Capex Intensity
DGX
DGX
IVZ
IVZ
Q1 26
3.9%
Q4 25
5.6%
1.4%
Q3 25
5.1%
1.2%
Q2 25
3.9%
1.2%
Q1 25
4.4%
1.5%
Q4 24
4.7%
0.4%
Q3 24
4.3%
1.9%
Q2 24
3.8%
1.8%
Cash Conversion
DGX
DGX
IVZ
IVZ
Q1 26
0.99×
Q4 25
1.90×
Q3 25
2.30×
1.70×
Q2 25
1.93×
2.78×
Q1 25
1.43×
-0.49×
Q4 24
2.09×
1.51×
Q3 24
1.58×
7.97×
Q2 24
1.57×
3.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DGX
DGX

Segment breakdown not available.

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

Related Comparisons